Drugs.com - Clinical Trials

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer

PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and...

Mar 9, 2025 - 23:09
 0
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer
PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and...
Read More

Tags:

Previous Article

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempiki...

Next Article

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial fo...

Related Posts

Boehringer’s Zongertinib Receives Priority Review from U.S. FDA for the Treatment of HER2 (ERBB2)-Mutant Advanced Non-Small Cell Lung Cancer

Boehringer’s Zongertinib Receives Priority Review from ...

Feb 20, 2025  0

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist and Takeda Announce Positive Topline Result...

Mar 3, 2025  0

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Zai Lab Receives Orphan Drug Designation from the U.S. ...

Feb 9, 2025  0